Home Cart Sign in  
Chemical Structure| 14542-12-2 Chemical Structure| 14542-12-2

Structure of 14542-12-2

Chemical Structure| 14542-12-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 14542-12-2 ]

CAS No. :14542-12-2
Formula : C4H5NOS
M.W : 115.15
SMILES Code : OCC1=NC=CS1
MDL No. :MFCD06200855
InChI Key :JNHDLNXNYPLBMJ-UHFFFAOYSA-N
Pubchem ID :2795213

Safety of [ 14542-12-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 14542-12-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 7
Num. arom. heavy atoms 5
Fraction Csp3 0.25
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 28.24
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

61.36 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.39
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.1
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.48
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.88
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.01
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.62

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.08
Solubility 9.59 mg/ml ; 0.0833 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.94
Solubility 13.1 mg/ml ; 0.114 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.07
Solubility 9.85 mg/ml ; 0.0855 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.93 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.11

Application In Synthesis of [ 14542-12-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 14542-12-2 ]
  • Downstream synthetic route of [ 14542-12-2 ]

[ 14542-12-2 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 10200-59-6 ]
  • [ 14542-12-2 ]
YieldReaction ConditionsOperation in experiment
93% With sodium tetrahydroborate In methanol at 0℃; for 2 h; Thiazole-2-carbaldehyde (301 mg, 2.66 mmol) was dissolved in methanol (15 mL) at 0 ° C,Sodium borohydride (151 mg, 3.99 mmol) was added to the system and reacted for 2 h. The reaction solution was poured into water (10 mL)The solvent was spin-dried, extracted with ethyl acetate (15 mL × 3), washed with saturated brine (15 mL), dried over anhydrous sodium sulfate,The solvent was removed and the residue was subjected to column chromatography (eluent:PE / EtOAc (v / v) = 5/1) to give 285 mg of a pale yellow oil, yield: 93percent.
82%
Stage #1: With sodium tetrahydroborate In methanol at 0 - 20℃; for 1 h;
Manufacturing Example 88-1-1 Thiazole-2-yl-methanol; To a mixture of 2-formylthiazole (300 mg, 2.65 mmol) and methanol (30 mL) was added sodium borohydride (201.0 mg, 5.30 mmol) at 0° C., which was stirred for 1 hour at room temperature. Water was added to this reaction mixture, which was then extracted with ethyl acetate. The organic layer was separated, washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under a reduced pressure, and the residue was purified by NH silica gel column chromatography (diethyl ether) to obtain the title compound (251.2 mg, 82percent).1H-NMR Spectrum (DMSO-d6) δ (ppm): 4.74 (2H, d, J=6.0 Hz), 6.04 (1H, t, J=6.0 Hz), 7.63-7.65 (1H, m), 7.73-7.75 (1H, m).
74% With sodium tetrahydroborate In methanol at -60℃; for 2 h; A stirred and cooled (-60 °C) sol. of thiazole-2-carbaldehyde (3.97 g, 35.1 mmol) in MeOH (35 mL) was treated with NaBH4 (1.33 g, 35.1 mmol). The reaction mixture was stirred at -60 °C for 2 h, then carefully quenched with acetone (2.7 mL), and allowed to warm to rt. The solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc) yielded the title compound (3 g, 74percent) as an orange oil that crystallized at -20 °C, and remained a solid upon warming to rt. LC-MS: tR = 0.26 min, ES+: 116.13.
74% at -60℃; for 2 h; A stirred and cooled (-60 0C) sol. of thiazole-2-carbaldehyde (3.97 g, 35.1 mmol) in MeOH (35 mL) was treated with NaBH4 (1.33 g, 35.1 mmol). The reaction mixture was stirred at -60 0C for 2 h, then carefully quenched with acetone (2.7 mL), warmed to rt, and the solvents were removed in vacuo. Purification of the crude by FC (EtOAc) yielded the title compound (3.00 g, 74percent) as an orange oil that crystallized at -20 0C and remained a solid upon warming to rt.
66%
Stage #1: With sodium tetrahydroborate In methanol at 0℃;
Stage #2: With water In methanol
Referential Example 12: thiazole-2-methanol
While stirring under ice cooling, sodium borohydride (242 mg, 6.40 mmol) was added to a methanol (10 ml) solution of 2-formylthiazole (483 mg, 4.27 mmol)..
After completion of the reaction was confirmed, water was added to the reaction mixture..
The resulting mixture was concentrated under reduced pressure..
Water and ethyl acetate were added to the residue to separate the organic layer..
The organic layer was washed with brine and then dried over anhydrous sodium sulfate..
After filtration, the filtrate was concentrated under reduced pressure..
The residue was subjected to chromatography on a silica gel column..
The fraction obtained from the hexane:ethyl acetate (=1:1) elude was concentrated under reduced pressure, whereby the title compound (324 mg, 66percent) was obtained as a white solid.1H-NMR (400MHz, CDCl3) δ: 3.30-3.70(1H,m), 5.14(2H,s), 7.32(1H,d,J=3.4Hz), 7.74(1H,d,J=3.2Hz). MS (m/z): 116 (M++H).
62% With sodium hydroxide; sodium tetrahydroborate In methanol b.
2-(Hydroxymethyl)thiazole
To a cooled solution (0° C.) of 2-formylthiazole (described in example 71a) (1.50 g, 13.27 mmol) in methanol (25 mL) under nitrogen was added sodium borohydride (0.300 g, 7.94 mmol).
After the addition was complete, the reaction was warmed to room temperature over 1 h and stirred at room temperature for 3 h.
Excess reagent was quenched with acetone (10 mL) and stirred 18 h.
The reaction was acidified with 3N HCl (25 mL), cooled to 0° C. and rebasified with 2.5N NaOH (40 mL).
The aqueous phase was extracted with ethyl acetate (3*25 mL).
Combined organic extracts were dried over anhydrous magnesium sulfate, filtered and reduced to a relatively pure oil in 62percent yield. TLC analysis (Rf 0.15, 40percent ethyl acetate in hexane).
No further purification was required. MS (CI, CH4) m/z 116 (M+1,82), 144 (M+29,17), 98 (100).
60% With sodium borohydrid In methanol Example 391A
1,3-thiazol-2-ylmethanol
To thiazole-2-carbaldehyde (1133 mg, 1 mmol) in methanol (10 mL) was added sodium borohydride (41 mg, 1.2 mmol) portion wise at 0° C.
The mixture was stirred at room temperature for 2 hours.
The mixture was diluted with water and acidified to pH 3 with 1M hydrochloric acid, and extracted with ethyl acetate (2*50 mL).
The organic layers were washed with saturated aqueous sodium bicarbonate, water, brine, dried over magnesium sulfate, filtered and concentrated to give the title compound (69 mg, 60percent).
58% With sodium tetrahydroborate In methanol at 0℃; for 3 h; Aldehyde 3 (5.8 g, 51.3 mmol, 1 eq)/10 mL methanol was treated with NaBH4 (2.1 g,1.1 eq) at 0 °C for 3 h. The solvent was removed and EtOAc was added forextraction. Flash chromatography (2:1 Hexane : EtOAc) provided 3.4 g of the desiredproduct (58 percent yield).1H NMR (CDCI3 8): 4.90 (s, 2H) 7.27 (m, 1H) 7.70
56%
Stage #1: With sodium tetrahydroborate In ethanol for 16 h; Heating / reflux
Stage #2: With water In ethyl acetate
0.20 ml (2.28 mmol) 2-thiazolecarboxaldehyde are placed in 10 ml of ethanol, 0.172 g (4.55 mmol) sodium borohydride are added.
The reaction mixture is refluxed for 16 hours with stirring, then concentrated by evaporation.
The residue is extracted with water and ethyl acetate, the organic phase is washed with water.
The combined aqueous phases are saturated with sodium chloride and extracted with ethyl acetate.
The resulting organic phase is dried and evaporated to dryness.
Yield: 0.146 g (=56percent of theoretical)
56%
Stage #1: With sodium tetrahydroborate In ethanol at 20℃; for 16 h; Heating / reflux
Stage #2: With water In ethyl acetate
Precursor for compound 17: thiazol-2-yl-methanol
0.20 ml (2.28 mmol) 2-thiazol-carboxaldehyde are placed in 10 ml of ethanol at ambient temperature, 172 mg (4.55 mmol) sodium borohydride are added and then the mixture is refluxed for 16 hours with stirring.
Then the reaction mixture is concentrated by evaporation, the residue is extracted with water and ethyl acetate.
The aqueous phase is saturated with sodium chloride and extracted again with ethyl acetate.
The resulting organic phase is dried and evaporated to dryness. Yield: 146 mg (=56percent of theoretical)
53%
Stage #1: With sodium tetrahydroborate In ethanol at 20℃; for 1.5 h;
Stage #2: With water In ethanol
Sodium borohydride (0.17 g, 4.49 mmol) was added to a solution * of 2- thiazolecarboxaldehyde (0.39 mL, 4.44 mmol) in ethanol (25 mL). After stirring for 1.5 h at room temperature, the reaction was quenched with water and concentrated. The residue was dissolved in ethyl acetate and washed with water and brine, dried over magnesium sulfate and concentrated to give 0.27 g, (53percent) of thiazol-2-yl-methanol as a tan oil which had: NMR (CDCI3) δ 7.72 (d, J = 3.3 Hz, 1 H), 7.31 (d, J = 3.3 Hz, 1 H), 4.95 9s, 2H); 2.83 (br s, 1 H). This was mixed with triethyl amine (0.33 mL, 2.37 mmol) in methylene chloride (4 mL) and cooled in ice. Methanesulfonylchloride (0.18 mL, 2.33 mmol) in methylene chloride (2mL) was added dropwise over 1 min. After 30 min stirring at O0C, the reaction was washed with water and brine, dried over magnesium sulfate and concentrated to yield 0.41 g (91 percent) of methanesulfonic acid thiazol-2-ylmethyl ester as an orange oil which had: NMR (CDCI3) δ 7.83 (d, J = 3.3 Hz, 1 H), 7.45 (d, J = 3.3 Hz, 1 H), 5.50 (s, 2H), 3.06 (s, 3H).
16.4% With sodium tetrahydroborate In methanol at -60℃; for 1 h; Inert atmosphere To a solution of n-BuLi (8.4 ml, 1.6 mol/l, 13.4 mmol) in THF (30 mL) was added 2-bromothiazole (377 mg, 2.12 mmol) dropwise under nitrogen atmosphere at -70° C., and the mixture was stirred at the temperature for 1 h.
Then DMF (1.4 ml, 18.3 mmol) was added into the solution dropwise under nitrogen atmosphere at -70° C.
The resulting mixture was stirred at the temperature for 1 h.
Then the mixture was quenched with aqueous saturated ammonium chloride, diluted with ethyl acetate and water, and the phases were separated.
The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to give yellow oil.
The yellow oil was dissolved in methanol (15 ml), cooled to -60° C., and sodium borohydride (463 mg, 12.2 mmol) was added portionwise under nitrogen atmosphere.
The mixture was stirred at the temperature for 1 h.
The reaction was quenched with acetone and concentrated.
The residue was diluted with ethyl acetate and water, and the phases were separated.
The organic layer was dried over sodium sulfate, filtered and concentrated, then purified by silica gel chromatography eluting with petroleum/ethyl acetate=3:1 to give thiazol-2-ylmethanol (230 mg, 16.4percent yield) as brown oil. LCMS MH+ 116.
15.2% With sodium tetrahydroborate In methanol at 0℃; for 2 h; To a solution of 18a (20.55 g, 0.18 mol) in MeOH (100 mL) was added NaBH4 (7.6 g, 0.20 mol) at 0°C. The reaction mixture was stirred at 0°C for 2 hours and monitored using TLC. Then, acetone (20 mL) was added into the solution and stirred for 20 minutes and the mixture was concentrated in vacuo. After that, the residue was washed with water (200 mL) and extracted with ethyl acetate (300 mL), washed with brine and dried over anhydrous sodium sulfate. After concentration in vacuo, and the resutling residue was purified using Si02 chromatography, eluting with petroleum ether: ethyl acetate (10/1-1/1) to provide 18b (3.18 g, 15.2percent)
15.2% With sodium tetrahydroborate In methanol at 0℃; for 2 h; To a solution of 18a (20.55 g, 0.18 mol) in MeOH (100 mL) was added NaBH4 (7.6 g, 0.20 mol) at 0°C. The reaction mixture was stirred at 0°C for 2 hours and monitored using TLC. Then, acetone (20 mL) was added into the solution and stirred for 20 minutes and the mixture was concentrated in vacuo. After that, the residue was washed with water (200 mL) and extracted with ethyl acetate (300 mL), washed with brine and dried over anhydrous sodium sulfate. After concentration in vacuo, the residue was purified using Si02 chromatography, eluting with petroleum ether: ethyl acetate (10/1-1/1) to provide 18b (3.18 g, 15.2percent).
12 g With sodium tetrahydroborate In methanol at 0 - 20℃; To a mixture of 2-formylthiazole (84.22g, 0.75mol) and methanol (100 mL) was added sodium borohydride (120g, 1.5mol) at 0°C, which was stirred for overnight at room temperature. Water was added to this reaction mixture, which was then extracted with ethyl acetate. The organic layer was separated, washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under a reduced pressure, and the residue was purified by silica gel column chromatography with DCM/MeOH (100:1-50:1) to afford thiazol-2-ylmethanol as light yellow oil (12 g ,14percent).
230 mg at -60℃; for 1 h; Inert atmosphere Step 1 thiazol-2-ylmethanol To a solution of n-BuLi (8.4 ml , 1.6 mol/1 , 13.4 mmol) in THF (30 mL) was added 2- bromothiazole (377 mg, 2.12 mmol) dropwise under nitrogen atmosphere at -70 °C, and the mixture was stirred at the temperature for 1 h. Then DMF (1.4 ml, 18.3 mmol) was added into the solution dropwise under nitrogen atmosphere at -70 °C. The resulting mixture was stirred at the temperature for 1 h. Then the mixture was quenched with aqueous saturated ammonium chloride, diluted with ethyl acetate and water, and the phases were separated. The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to give yellow oil. The yellow oil was dissolved in methanol (15 ml) , cooled to -60 °C, ans sodium borohydride (463 mg , 12.2 mmol) was added portionwise under nitrogen atmosphere. The mixture was stirred at the temperature for 1 h. The reaction was quenched with acetone and concentrated. The residue was diluted with ethyl acetate and water, and the phases were separated. The organic layer was dried over sodium sulfate, filtered and concentrated, then purified by silica gel chromatography eluting with petroleum/ ethyl acetate= 3: 1 to give thiazol-2-ylmethanol (230 mg, 16.4 percent yield) as brown oil . LCMS MH+ 1 16.

References: [1] Chinese Journal of Chemistry, 2014, vol. 32, # 6, p. 538 - 544.
[2] Patent: CN106749268, 2017, A, . Location in patent: Paragraph 0798; 0799.
[3] European Journal of Organic Chemistry, 2017, vol. 2017, # 33, p. 4972 - 4983.
[4] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2007, vol. 62, # 12, p. 1525 - 1529.
[5] Tetrahedron, 1988, vol. 44, # 7, p. 2021 - 2032.
[6] Patent: US2009/82403, 2009, A1, . Location in patent: Page/Page column 147-148.
[7] Patent: WO2006/21402, 2006, A1, . Location in patent: Page/Page column 36.
[8] Patent: WO2006/92268, 2006, A1, . Location in patent: Page/Page column 22-23.
[9] Patent: EP1466898, 2004, A1, . Location in patent: Page 90.
[10] Patent: US5512575, 1996, A, .
[11] Patent: US2004/162285, 2004, A1, .
[12] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 17, p. 4845 - 4850.
[13] Patent: WO2006/19957, 2006, A2, . Location in patent: Page/Page column 25.
[14] Patent: US2006/116372, 2006, A1, . Location in patent: Page/Page column 7.
[15] Patent: US2006/116372, 2006, A1, . Location in patent: Page/Page column 7.
[16] Patent: WO2007/34277, 2007, A1, . Location in patent: Page/Page column 55.
[17] Patent: US2014/275528, 2014, A1, . Location in patent: Paragraph 0304; 0305.
[18] Patent: WO2014/110705, 2014, A1, . Location in patent: Page/Page column 75.
[19] Patent: WO2014/110687, 2014, A1, . Location in patent: Page/Page column 56.
[20] Journal of Organic Chemistry, 1995, vol. 60, # 15, p. 4749 - 4754.
[21] Journal of Materials Chemistry, 1998, vol. 8, # 4, p. 833 - 835.
[22] Patent: WO2006/46031, 2006, A1, . Location in patent: Page/Page column 76-77.
[23] Patent: US2009/170907, 2009, A1, . Location in patent: Page/Page column 60.
[24] Patent: EP1422228, 2004, A1, . Location in patent: Page 221.
[25] Patent: EP1443041, 2004, A1, . Location in patent: Page 27.
[26] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 24, p. 7414 - 7420.
[27] Patent: WO2013/80222, 2013, A1, . Location in patent: Page/Page column 33.
[28] Patent: WO2014/66795, 2014, A1, . Location in patent: Paragraph 0174 - 0175.
[29] Patent: WO2014/143799, 2014, A2, . Location in patent: Page/Page column 386; 387.
[30] Patent: US2016/137639, 2016, A1, . Location in patent: Paragraph 3410.
  • 2
  • [ 288-47-1 ]
  • [ 14542-12-2 ]
References: [1] Patent: US5821246, 1998, A, .
  • 3
  • [ 14527-42-5 ]
  • [ 14542-12-2 ]
References: [1] Tetrahedron, 1988, vol. 44, # 7, p. 2021 - 2032.
  • 4
  • [ 54101-88-1 ]
  • [ 14542-12-2 ]
References: [1] Tetrahedron, 1991, vol. 47, # 16, p. 2851 - 2860.
  • 5
  • [ 16733-85-0 ]
  • [ 14542-12-2 ]
References: [1] Acta Chemica Scandinavica (1947-1973), 1967, vol. 21, p. 389 - 396.
  • 6
  • [ 288-47-1 ]
  • [ 50-00-0 ]
  • [ 14542-12-2 ]
References: [1] J. Gen. Chem. USSR (Engl. Transl.), 1961, vol. 31, p. 1255 - 1259[2] Zhurnal Obshchei Khimii, 1961, vol. 31, p. 1356 - 1361.
  • 7
  • [ 40610-14-8 ]
  • [ 50-00-0 ]
  • [ 14542-12-2 ]
References: [1] Acta Chemica Scandinavica (1947-1973), 1966, vol. 20, p. 2649 - 2657.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 14542-12-2 ]

Alcohols

Chemical Structure| 202932-04-5

A136768 [202932-04-5]

5-Methyl-2-thiazolemethanol

Similarity: 0.87

Chemical Structure| 475059-74-6

A582660 [475059-74-6]

(4-(tert-Butyl)thiazol-2-yl)methanol

Similarity: 0.67

Chemical Structure| 204319-69-7

A272385 [204319-69-7]

(4-(Trifluoromethyl)thiazol-2-yl)methanol

Similarity: 0.66

Chemical Structure| 131748-97-5

A205959 [131748-97-5]

(2-(Trifluoromethyl)thiazol-5-yl)methanol

Similarity: 0.63

Chemical Structure| 38585-74-9

A215012 [38585-74-9]

Thiazol-5-ylmethanol

Similarity: 0.63

Related Parent Nucleus of
[ 14542-12-2 ]

Thiazoles

Chemical Structure| 202932-04-5

A136768 [202932-04-5]

5-Methyl-2-thiazolemethanol

Similarity: 0.87

Chemical Structure| 3581-87-1

A563595 [3581-87-1]

2-Methylthiazole

Similarity: 0.83

Chemical Structure| 14190-59-1

A126971 [14190-59-1]

Thiazole-2-carboxylic acid

Similarity: 0.80

Chemical Structure| 53332-78-8

A134697 [53332-78-8]

Thiazol-2-ylmethanamine dihydrochloride

Similarity: 0.75

Chemical Structure| 55661-33-1

A288400 [55661-33-1]

Thiazol-2-ylmethanamine

Similarity: 0.75